[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Germans Trias i Pujol Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":283},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,78,103,129,160,203,230,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645417","study-of-the-brains-natural-cleaning-system-in-potential-organ-donors-100645417",false,"NCT07682155","Study of the Brain's Natural Cleaning System in Potential Organ Donors.","Study of Drainage From the Cerebral Lymphatic System to Deep Cervical Nodes by the Migration of Indocyanine Green in Recent Cadaver","ICGBRAIN","Inclusion Criteria:\n\n* Potential organ donor patients, both in Brain Death and in Controlled Asystole, candidates to perform organ harvesting authorized by the Transplant and Tissue Coordination of the Universitary Germans Trias i Pujols Hospital, according to the usual channels and whose family members have previously signed the authorization of the donation and the specific informed consent of the study. Will be included in the study always after death is certified by neurological or cardiocirculatory criteria\n\nExclusion Criteria:\n\n* Absence of informed consent signed by family members.\n* Individuals with a history of having intracranial lymphatic drainage affected.",true,"ALL",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","Alzheimer's disease is a condition that affects the brain and is associated with the build-up of waste substances that can damage brain cells. Scientists have recently discovered a natural drainage and cleaning system around the brain, called the meningeal lymphatic system, which may help remove these waste products.\n\nResearchers believe that this brain drainage system is connected to lymph nodes located in the neck. However, this connection has not yet been clearly demonstrated in humans because it is difficult to study.\n\nThe purpose of this study is to investigate how fluid drains from the brain to the lymph nodes in the neck. To do this, researchers will use a fluorescent dye called indocyanine green, which can be seen with a special camera. The study will be carried out in potential organ donors who have been authorized for organ donation.\n\nThe researchers will record images and videos to observe how the dye moves, how long it takes to reach the lymph nodes, whether the drainage is similar on both sides of the body, and which lymph nodes are involved.\n\nA better understanding of these drainage pathways may help researchers develop and improve future treatments for Alzheimer's disease and other neurological disorders.",[27],"Anatomical Description",[29,30,31],"Alzheimer's disease","meningeal lymphatic system","cervical lymph nodes","RECRUITING","2026-06-26",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2026-02-01",{"date":40,"type":21},"2026-12-31",{"name":42,"class":43},"Germans Trias i Pujol Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100633682","ai-based-echocardiography-for-detection-of-cardiac-amyloidosis-100633682","NCT07529860","AI-based Echocardiography for Detection of Cardiac Amyloidosis","AI-based Echocardiography for Detection of Cardiac Amyloidosis in Patients Undergoing Transthoracic Echocardiography With Left Ventricular Hypertrophy","ORCHESTRA","Inclusion Criteria:\n\n* Patients 18 years old or older\n* Left ventricular hypertrophy defined by a wall thickness of at least 12 mm\n* Echocardiographic red flags of suspected cardiac amyloidosis\n* Informed consent signed\n\nExclusion Criteria:\n\n* Patients with poor echocardiographic acoustic window to allow proper analysis of the data\n* Patients with known cardiac amyloidosis.","18 Years","95 Years",{"count":56,"type":21},200,[24],"Cardiac amyloidosis is characterized by deposition of misfolded protein in the myocardium causing mainly heart failure symptoms with preserved left ventricular ejection fraction. There are also specific clinical (bilateral carpal tunnel syndrome, polyneuropathy, skin bruising, ruptured biceps tendon…), biomarkers (disproportionally elevated NT-proBNP to the degree of heart failure, persistent elevated troponin, proteinuria..), electrocardiographic (reduced voltage of QRS, atrial fibrillation..) and echocardiographic features (concentric left ventricular hypertrophy, dilated atria, reduced global longitudinal strain with typical pattern of apical sparing, diastolic dysfunction…). Early diagnosis of the disease is crucial to identify patients that may benefit from appropriate treatment. Suspected cardiac amyloidosis on echocardiography or on cardiac magnetic resonance needs to prompt the request of serum free-light chain quantification and serum and urine immunofixation as well as single photon emission computed tomography (SPECT) using bone radiotracers. Echocardiography is the imaging technique of first choice to evaluate patients with dyspnea complaints and suspected heart failure as well as other pathologies. Echocardiography is a technique of first choice to evaluate patients with cardiovascular risk factors such as arterial hypertension and diabetes and many of those patients may have echocardiographic features that can be observed in early phases of cardiac amyloidosis. Currently, identification of patients with cardiac amyloidosis with available echocardiographic tools remains challenging. However, novel artificial intelligence (AI)-based algorithms applied to echocardiographic images for analysis may help the cardiologists in the identification of early phase of cardiac amyloidosis. Early diagnosis of cardiac amyloidosis is key to implement effective therapies that have demonstrated to improve survival. Several studies have demonstrated the accuracy of AI-based algorithms applied to echocardiography for the diagnosis of cardiac amyloidosis. The hypothesis of the present prospective study is to evaluate the accuracy of the AI-based algorithm to identify patients with echocardiographic findings suggestive of cardiac ATTR amyloidosis using as ground truth the subsequent analysis with imaging techniques that permit its diagnosis such as 99mTc-pyrophosphate (PYP) SPECT and cardiac magnetic resonance as well as hematologic tests. If needed, histological confirmation on cardiac or extracardiac tissue could be performed, as recommended by recent consensus document from the Heart Failure Association of the European Society of Cardiology.\n\nIn addition, this study will help to answer the true prevalence of ATTR cardiac amyloidosis among patients referred to transthoracic echocardiography that present red flags for ATTR cardiac amyloidosis. The AI-based algorithm is the software Us2.ai which has been used in other populations for this purpose, as previously published.",[60,61,62],"Cardiac Amyloidosis","Heart Failure With Preserved Ejection Fraction (HFPEF)","Left Ventricular Hypertrophy",[64,65,66,67,68],"artifical intelligence","echocardiography","strain","cardiac amyloidosis","left ventricular hypertrophy","NOT_YET_RECRUITING","2026-06-10",{"date":72,"type":36},"2026-06-12",{"date":74,"type":21},"2026-07-01",{"date":76,"type":21},"2028-10",{"name":42,"class":43},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":85,"targetDuration":86,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":44},"100633599","novel-3-dimensional-echocardiographic-quantification-of-mitral-regurgitant-volume-100633599","NCT07528781","Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume","AIM_3D","Inclusion Criteria:\n\n* Patients with at least moderate mitral regurgitation of any etiology\n* Patients with good transesophageal echocardiography image quality\n\nExclusion Criteria:\n\n* Patients with prior transcatheter or surgical mitral valve intervention\n* Patients with contraindications for transesophageal echocardiography or cardiac magnetic resonance",{"count":56,"type":21},"2 Years","OBSERVATIONAL","The goal of this observational study is demonstrate that a novel artificial intelligence based software for the quantification of the mitral regurgitation on 3-dimensional transesophageal echocardiography (3D CFQ) is more reproducible and accurate than the conventional assessment of mitral regurgitation performed with 2-dimensional echocardiography. The main question aims to answer is to demonstrate the agreement between 3D-CFQ measurement of the mitral regurgitant volume and the cardiac magnetic resonance measurement of the regurgitant volume is better than the agreement between 2-dimensional echocardiography and cardiac magnetic resonance. If this is demonstrated, we would like to test the accuracy of this tool to be applied in acute settings such as transcatheter interventions to decide the therapy to follow.\n\nParticipants will undergo clinically indicated transesophageal echocardiography to characterize the mechanism and severity of mitral regurgitation and to cardiac magnetic resonance to be used as reference stadard to define the mitral regurgitation severity.",[90],"Moderate or Severe Mitral Regurgitation",[92,93,94],"mitral regurgitation","mitral valve surgery","transcatheter intervention","2026-04-09",{"date":97,"type":36},"2026-04-14",{"date":99,"type":21},"2026-03-17",{"date":101,"type":21},"2028-04-01",{"name":42,"class":43},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100597341","chronic-insomnia-in-non-cancer-pain-patients-100597341","NCT07057232","Chronic Insomnia in Non-Cancer Pain Patients","Estimating the Prevalence of Chronic Insomnia in Patients With Non-cancer Chronic Pain","PainSomnia","Inclusion Criteria:\n\n* Aged 18 years or older\n* Either biological sex\n* Diagnosed with chronic non-cancer pain\n* Receiving care in a pain unit or by a pain specialist\n* Able to understand and participate in the study\n* Who sign informed consent\n\nExclusion Criteria:\n\n* Deemed unable or unlikely to cooperate adequately with study procedures at the discretion of the pain specialist or investigator",{"count":112,"type":21},385,"Pain and sleep are closely linked physiological processes that support overall health and functioning. Increasing evidence shows a dynamic, bidirectional relationship: poor sleep increases pain sensitivity, while chronic pain disrupts normal sleep. Both conditions are highly prevalent and significantly impair quality of life, making them major public health concerns.\n\nChronic pain, defined as pain lasting more than three months, affects around 17% of adults in Spain. Insomnia, though common, is harder to define due to its overlap with medical and psychiatric conditions. It may present as a symptom, a syndrome, or a formal sleep disorder, leading to variability in prevalence estimates.\n\nCurrent diagnostic criteria, including DSM-5 and the International Classification of Sleep Disorders, Third Edition (ICSD-3), adopt the unified concept of chronic insomnia disorder, defined as persistent difficulty with sleep initiation, maintenance, or quality, despite adequate opportunity for sleep, and associated with daytime impairment.\n\nICSD-3 distinguishes three types of insomnia:\n\n* Chronic insomnia disorder: symptoms ≥3 times\u002Fweek for ≥3 months;\n* Short-term insomnia disorder: symptoms lasting less than 3 months;\n* Other insomnia disorder: symptoms not meeting criteria for the above.\n\nAbout one-third of the general population reports insomnia symptoms. However, when both night symptoms and daytime impact are considered, the prevalence of chronic insomnia disorder is estimated at 6-10%. Women are more frequently affected, with a female-to-male ratio of about 1.4:1.\n\nDespite this, few studies have assessed insomnia specifically in people with chronic non-cancer pain. This gap is important, as untreated insomnia may worsen pain and reduce treatment efficacy, reinforcing a vicious cycle.\n\nThis observational study (PainSomnia) aims to estimate the prevalence of chronic insomnia among adults with chronic non-cancer pain. The results will help support integrated, individualized treatment approaches that address both sleep and pain in this high-risk population.",[115,116],"Chronic Non-cancer Pain","Insomnia",[116,118,119],"Chronic non-cancer pain","Prevalence","2025-07-09",{"date":122,"type":36},"2025-07-14",{"date":124,"type":36},"2025-06-09",{"date":126,"type":21},"2025-12",{"name":42,"class":43},15,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":136,"targetDuration":138,"studyType":87,"phases":4,"briefSummary":139,"conditions":140,"keywords":146,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":4},"100597896","spanish-registry-of-direct-cholangiopancreatoscopy-by-single-operator-100597896","NCT07064447","Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator","National Prospective Registry of Direct Cholangiopancreatoscopy by Single Operator","Inclusion Criteria:\n\n* Patients undergoing cholangiopancreatoscopy at the participating centers from 1 June 2025 will be included.\n* Be over 18 years of age.\n* Provide signed informed consent.\n\nExclusion Criteria:\n\n* Age under 18 years.\n* Lack of availability of signed informed consent.\n* Impossibility of follow-up.",{"count":137,"type":21},260,"1 Year","Endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) remain fundamental tools for the diagnosis and treatment of many pancreatobiliary diseases.\n\nHowever, there are situations in which these procedures face limitations, such as the evaluation of indeterminate ductal strictures or the management of complex choledocholithiasis.\n\nDirect visualization of the biliary and pancreatic ducts has proven to be a useful and effective alternative in such cases. It also has a safety profile comparable to conventional ERCP, with only a slight increase in the incidence of adverse events.\n\nNevertheless, due to the associated increase in costs, most centers have adopted a stepwise approach in their diagnostic and therapeutic algorithms, using this technique only after multiple ERCPs.\n\nAlthough the evidence is still limited, recent studies suggest that early use of direct cholangiopancreatoscopy could be a cost-effective strategy due to its increased efficacy.\n\nIn this regard, collecting data on direct cholangiopancreatoscopy would be of interest to generate robust conclusions on cost-effectiveness in routine clinical practice.\n\nThis study aims to objectively assess the real-world use of direct cholangiopancreatoscopy in our setting, with the goal of confirming technical aspects, efficacy, and safety, and ultimately conducting cost-effectiveness evaluations to determine the optimal point in the algorithm at which this technique should be introduced.",[141,142,143,144,145],"Cholangiocarcinoma","Cholangiopathy","Biliary Stricture","Choledocholithiasis","Pancreatic Cancer",[147,148,149,150,151,152],"Cholangiopancreatoscopy","indeterminate biliary stricture","choledocholitiasis","pancreatic cancer","cost-effectiveness","algorithm","2025-07-03",{"date":122,"type":36},{"date":156,"type":21},"2025-09-01",{"date":158,"type":21},"2026-06-30",{"name":42,"class":43},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":167,"minAge":53,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":187,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":44},"100593584","impact-of-nipple-reconstruction-in-mastectomized-patients-using-cross-linked-hyaluronic-acid-injection-100593584","NCT07008339","Impact of Nipple Reconstruction in Mastectomized Patients Using Cross-Linked Hyaluronic Acid Injection.","RECHIAL","* Quantitative Phase\n* Inclusion Criteria:\n\nWomen over 18 years of age, or with parental or legal guardian consent.\n\nAt least one of the following criteria:\n\nWomen undergoing their first nipple-areola complex (NAC) reconstruction through micropigmentation and\u002For:\n\nNo previous neo-nipple surgery, either unilaterally or bilaterally.\n\nSurgical reconstruction of the areola.\n\nSurgical reconstruction of the NAC with subsequent retraction of the neo-nipple.\n\nMore than 6 months since their last surgery.\n\n\\- Exclusion Criteria:\n\nAllergy to hyaluronic acid.\n\nPoor tolerance to needle injections.\n\nWithdrawal Criteria:\n\nParticipant's voluntary decision.\n\nComplications associated with the technique (allergy, hematoma, etc.).\n\nClinical deterioration preventing the woman from continuing in the study.\n\n\\- Qualitative Phase\n\nParticipant Profile Characteristics: For the qualitative phase, women who have received NAC reconstruction with HA will be invited to participate, following the maximum variation criterion. To ensure the inclusion of participants with diverse characteristics and capture a wide range of perspectives and experiences on the phenomenon under study, women of varying ages, with different breast cancer diagnoses, and histories of various oncological, surgical, and therapeutic treatments will be selected.","FEMALE",{"count":169,"type":21},138,[24],"This study evaluates the impact of hyaluronic acid (HA) injection for nipple projection following mastectomy, as a complement to areola micropigmentation. While micropigmentation is standard in nipple-areola complex (NAC) reconstruction, HA use remains novel, with limited data on psychosocial, sexual, and aesthetic outcomes.\n\nA sequential explanatory mixed-methods design will be used. In Phase 1, a randomized controlled trial will compare two groups: one receiving NAC micropigmentation alone (control) and the other receiving micropigmentation plus HA-based nipple projection (intervention). A total of 138 participants will be recruited at the Areolar Micropigmentation Unit of Germans Trias i Pujol University Hospital (Barcelona) over 36 months. Outcomes will include psychosocial and sexual well-being, satisfaction with breast and nipple appearance, and nipple projection, measured using the Spanish BREAST-Q, a custom satisfaction tool, and calipers.\n\nPhase 2 will involve a qualitative phenomenological study using semi-structured interviews with a purposive sample from the intervention group. Thematic analysis will explore body image, emotional and social well-being, and overall satisfaction, using NVivo software.\n\nThis is the first study assessing HA nipple reconstruction by advanced practice nurses using validated patient-reported outcomes. While the BREAST-Q is appropriate, it may not fully capture emotional nuances, justifying qualitative exploration. HA durability is estimated at 6-9 months, but residual volume and satisfaction over time remain underexplored. HA's aesthetic footprint may allow reduced dosages in future applications.\n\nThis minimally invasive technique may reduce the need for surgical nipple reconstruction. Conducting the procedure in a nurse-led setting is novel and may enhance patient-centered care and the role of nursing in post-mastectomy recovery.\n\nThe study complies with the Declaration of Helsinki and Spanish biomedical regulations. Ethical approval was obtained. Participants will provide informed consent, and data will be anonymized and securely stored.",[173,174,175,176,177,178,179,180,181,182,183,184,185,186],"Breast Neoplasms","Mastectomy","Mammaplasty","Nipple Disorder","Tattooing","Hyaluronic Acid","Dermal Fillers","Reconstructive Surgical Procedures","Quality of Life","Self Concept","Body Image","Patient Satisfaction","Breast Reconstruction","Nipple Reconstruction",[188,174,185,189,186,190,178,179,191,177,183,181,192,193,184,194],"Breast Cancer","Nipple-Areola Complex Reconstruction","Areola Reconstruction","Micropigmentation","Postmastectomy Reconstruction","Cross-linked Hyaluronic Acid","Breast Cancer Survivors","2025-06-04",{"date":197,"type":36},"2025-06-06",{"date":199,"type":36},"2023-06-02",{"date":201,"type":21},"2029-07-02",{"name":42,"class":43},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":210,"targetDuration":212,"studyType":87,"phases":4,"briefSummary":213,"conditions":214,"keywords":220,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":229,"locationsCount":4},"100567619","spanish-registry-of-quality-indicators-and-adverse-events-of-endoscopic-retrograde-cholangiopancreatography-100567619","NCT06670547","Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography","Prospective and Multicenter Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography","Inclusion Criteria:\n\nAll consecutive patients who have undergone an ERCP at participating centres from 1 November 2024 will be included. An ERCP will be considered to have been performed when an endoscope is introduced to access the duodenal papilla.\n\nThese included patients must meet all of the following criteria:\n\n* Over 18 years of age\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Unavailability of informed consent\n* Impossibility of follow-up.",{"count":211,"type":21},3000,"30 Days","Endoscopic retrograde cholangiopancreatography (ERCP) is a technique which combines endoscopic and radiological vision and allows for therapeutic procedures on pathologies of the pancreas and bile duct.\n\nERCP is a generally well tolerated procedure, nonetheless it is a complex technique that has a higher frequency of complications compared to most endoscopic procedures that can even be life-threatening. These complications are related to patient characteristics, experience of the endoscopist performing the procedure, and specific factors to the technique. Due to its complexity, quality assurance, operator training and auditing are required to increase success and minimize complications.\n\nThere are quality indicators suggested by the main scientific societies in relation to technical aspects and complications, recommending their monitoring and auditing. Most endoscopy units lack records to monitor quality and complications, which prevents the assessment of quality and the identification of areas for improvement.\n\nGiven the lack of evidence of the quality of ERCP in the Spanish population, the investigators will be conducting a multicenter, national prospective study that will include subjects who undergo ERCP.\n\nPatient data and technical aspects of the procedure will be recorded and all included patients will be monitored to identify complications. The quality indicators obtained within the registry will be compared with those established by scientific societies and the relationship between complications and technical factors will be analyzed.",[144,215,141,216,217,218,219],"Choledocholithiasis With Acute Cholangitis","Sclerosing Cholangitis","Pancreatic Cancer Resectable","Pancreatic Cancer Non-resectable","Biliary Fistula",[221,222],"ERCP ADVERSE EVENTS","PERFORMANCE MEASURES","2024-10-31",{"date":225,"type":36},"2024-11-01",{"date":225,"type":21},{"date":228,"type":21},"2028-10-30",{"name":42,"class":43},{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":167,"minAge":53,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":245,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":44},"100555613","comparison-of-the-analgesic-effect-of-subsartorial-saphenous-block-and-popliteal-sciatic-vs-subsartorial-saphenous-block-and-ipack-in-total-knee-replacement-surgery-100555613","NCT06514365","Comparison of the Analgesic Effect of Subsartorial Saphenous Block and Popliteal Sciatic vs Subsartorial Saphenous Block and IPACK in Total Knee Replacement Surgery.","Comparison of the Analgesic Effect of Subsartorial Saphenous Block and Popliteal Sciatic vs Subsartorial Saphenous Block and IPACK in Total Knee Replacement Surgery. A Double Blind Randomized Clinical Trial.","Inclusion Criteria:\n\n* Patients with osteoarthritis scheduled for total primary knee arthroplasty with same surgeons\n* Locoregional anesthesia\n* Age equal to or greater than 18 years\n* Consent to participate in the study\n\nExclusion Criteria:\n\n* Age under 18 years old\n* General anesthesia\n* Allergy to local anesthetics\n* Severe kidney failure (Cr ≥ 2mg \u002F dL)\n* Chronic opioid use (over 3 months)\n* Chronic pregabalin \u002F gabapentin use (more than 3 months)\n* Psychiatric illness that may interfere with the evaluation or follow-up",{"count":238,"type":21},62,[24],"Total knee replacement surgery is associated with significant pain in the immediate postoperative period, especially in movement. In turn, this is associated with more subsequent chronic pain.\n\nThere are multiple options and the tendency is to perform increasingly distal nerve blocks to minimize limb weakness and thus allow early rehabilitation. In 2012, in an oral communication, Sanjay Sinha described a new nerve block called iPACK (\"Interspace between the Popliteal Artery and the Capsule of the posterior Knee\"). There are few studies on the efficacy of such a blockade so far, but none comparing the groups saphene + sciatic blocks vs. saphene + iPACK blocks.\n\nTherefore, this study aims to provide more information on the effectiveness this nerve blocks, in total knee replacement, in terms of analgesia and motor function.",[242,243,244],"Pain, Acute","Knee Osteoarthritis","Anesthesia",[246,247,248],"Ipack","Block","Total knee replacement","2024-07-16",{"date":251,"type":36},"2024-07-23",{"date":253,"type":36},"2020-06-10",{"date":255,"type":21},"2024-08-01",{"name":42,"class":43},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":267,"conditions":268,"keywords":273,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":44},"100542028","precision-psychiatry-for-depression-immune-response-and-affective-symptoms-as-predictors-of-response-to-antidepressants-100542028","NCT06337539","Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants","LYMPHODEP","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Clinical diagnosis of major depression according to DSM-5 criteria made by a psychiatrist applying the Structured Clinical Interview for DSM-5 (SCID-5).\n* Eligible for receiving antidepressant treatment for major depression.\n\nExclusion Criteria:\n\n* Who have received antidepressant, antipsychotic or euthymizer treatments in the 6 weeks prior to inclusion in the study.\n* Who present concurrent psychotic symptoms.\n* Who present disorders due to alcohol or drug use, with active consumption during the last 3 months.\n* Pregnant women.\n* Who have serious or unstable medical disorders, Addison's or Cushing's disease, systemic inflammatory or autoimmune diseases, or primary or secondary immunodeficiencies.","65 Years",{"count":266,"type":21},50,"Objectives: To identify in patients with major depression different peripheral markers of neuroinflammation in relation to affective symptoms (anxiety, depression, irritability), fatigue and cognitive symptoms; and its relationship with the response to antidepressant treatment with selective serotonin reuptake inhibitors (SSRIs).\n\nMethodology: This is a prospective observational cohort study in patients with major depression naturally subjected to treatment with SSRIs. For this, 30 patients with major depression attended in the Outpatient Psychiatry Consultations will be selected. All of them will be evaluated at baseline and after 3 months of treatment, collecting demographic and clinical variables, Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) psychiatric diagnoses, psychopathological scales and immunological and biochemical variables. The correlation between immunological markers and affective and cognitive symptoms at baseline, as well as their variation with treatment, will be analyzed. A group of 20 healthy subjects will be used as a control group.\n\nSubsequently, a bivariate comparative analysis will be carried out, where the statistically significant or marginally significant variables associated with psychopathological variables will be used to build a multivariate binary logistic regression model.",[269,270,271,272],"Depression","Inflammation","Antidepressants","Immunity",[274,269,270,272],"Selective serotonin reuptake inhibitors","2024-03-22",{"date":277,"type":36},"2024-03-29",{"date":279,"type":21},"2024-04-01",{"date":281,"type":21},"2027-07-31",{"name":42,"class":43},""]